Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (2601)	11/2/2010 5:18:42 PM
From: Jeffry K. Smith	Read Replies (1) \| Respond to of 3027

Dew, Thanks for your reply. You said you thought this might be part of a campaign to undermine investor confidence - but to what end? IOW, I could see how such a plan might to affect MNTA's ability to do a future stock offering or somesuch, but what other things/benefits might accrue to TEVA for waging a propaganda campaign? Understand, I'm not challenging your interpretation, just asking for clarification about the "why". Thanks again.

To: DewDiligence_on_SI who wrote (2601)	11/2/2010 5:32:31 PM
From: rkrw	1 Recommendation Respond to of 3027

Every brand company does everything they can do to prevent generic competition. File a series of weak patents, sue everyone for infringement, go for new formulations and new i.p and if all else fails, file aggressive Citizen's Petitions and settle to push it out a little bit more. I'm not quite sure what the generic Copaxone threat has to do with Teva seeking approval for generic Lovenox other than mnta is involved with both. The filing is already in and it's not as if a court case costs all that much money relatively. If Momenta hadn't filed on Copaxone would Teva be guiding analysts to not expect Lovenox approval?